21 Juni 2017

Obstructive Sleep Apnea .....

......Medication Leads to Skin Rash in Patient

A case report presented at the 2017 Annual Meeting of the Associated Professional Sleep Societies in Boston, MA, describes a patient who developed Stevens-Johnson Syndrome (SJS) within 2 weeks of armodafinil use.
Armodafinil, the R-enantiomer of modafinil, is indicated to improve wakefulness in patients with obstructive sleep apnea, narcolepsy, or shift work disorder. The mechanism by which armodafinil impacts wakefulness is still unclear, but it is an indirect dopamine receptor agonist with wake-promoting activity similar to sympathomimetics.
The patient, a 21-year-old female, presented with daytime sleepiness persisting since childhood even with 9 hours of sleep every night. She had a history of maintenance immunotherapy for common allergies, and showed significantly shortened sleep latencies without REM. She was diagnosed with idiopathic hypersomnia and was initiated on armodafinil 150mg every morning. More

Anxiety, Depression ......

......as Shared Experience in Couples

Couples are at high risk for affective concordance, particularly depression and anxiety, according to a new British study.
Defined as "shared emotional states in partners," affective concordance has garnered some research attention, but study findings have been inconsistent or have lacked rigor. J. Walker from the School of Medicine, Faculty of Medicine and Health Sciences, Keele University, Staffordshire, United Kingdom, and colleagues conducted a 1-year cross-sectional study to "enable a better understanding of what components influence concordance" and to "highlight which of these may be targets for future interventions." More

Depressive Symptoms......

......., Psychosocial Functioning Are Distinct Domains

Psychosocial functioning does not necessarily improve concurrently with depressive symptoms in patients with major depressive disorder (MDD) being treated with electroconvulsive therapy (ECT), according to a new study.
Ching-Hua Lin MD, PhD and colleagues, of the Kaohsiung Municipal Kai-Syan Psychiatric Hospital in Taiwan, studied 130 inpatients (age ≥18) with MDD being treated with ECT to explore whether functional improvement accompanied improvement in depressive symptoms.
Subjects required a 17-item Hamilton Depression Rating Scale (HAM-D17) score of ≥18 at baseline and to meet DSM-IV criteria for MDD. Psychosocial functioning was determined using the Modified Work and Social Adjustment Scale (MWSAS). The HAM-D17 and the MWSAS were administered before ECT, and then 1 to 2 days after every 3 ECT treatments, and after the final treatment. More